2023
Triple-Hormone-Receptor Agonist Retatrutide for Obesity. Reply.
Jastreboff A, Kaplan L, Hartman M. Triple-Hormone-Receptor Agonist Retatrutide for Obesity. Reply. New England Journal Of Medicine 2023, 389: 1629-1630. PMID: 37888927, DOI: 10.1056/nejmc2310645.Peer-Reviewed Original ResearchNaltrexone/bupropion for binge‐eating disorder: A randomized, double‐blind, placebo‐controlled trial
Grilo C, Lydecker J, Jastreboff A, Pittman B, McKee S. Naltrexone/bupropion for binge‐eating disorder: A randomized, double‐blind, placebo‐controlled trial. Obesity 2023, 31: 2762-2773. PMID: 37751990, PMCID: PMC10600891, DOI: 10.1002/oby.23898.Peer-Reviewed Original ResearchConceptsNaltrexone/bupropionBinge-eating disorderObesity statusLogistic regressionWeight lossPlacebo-controlled trialWeight loss outcomesPrevalent psychiatric disordersEvidence-based treatmentsPost-treatment assessmentBinge-eating frequencyGreater percentage weight lossMedication outcomesRemission ratePharmacological optionsPlaceboBupropionPsychiatric disordersPercentage weight lossMixed modelsDisordersObesityPatientsSignificant reductionWeight reductionReducing BMI below the obesity threshold in adolescents treated with once‐weekly subcutaneous semaglutide 2.4 mg
Kelly A, Arslanian S, Hesse D, Iversen A, Körner A, Schmidt S, Sørrig R, Weghuber D, Jastreboff A. Reducing BMI below the obesity threshold in adolescents treated with once‐weekly subcutaneous semaglutide 2.4 mg. Obesity 2023, 31: 2139-2149. PMID: 37196421, DOI: 10.1002/oby.23808.Peer-Reviewed Original ResearchConceptsWeekly subcutaneous semaglutideBMI categoriesSubcutaneous semaglutideWeek 68Glucagon-like peptide-1 receptor agonistsObesity thresholdPeptide-1 receptor agonistsHigh-intensity physical activityObesity class IIIOverweight BMI categoryLogistic regression modelsOverweight BMIReceiving placeboTeens trialLifestyle interventionReceptor agonistPhysical activityPlaceboBMISemaglutideParticipants' BMIClass IIIOverall populationPhase 3aHealthy nutritionTirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial
Garvey W, Frias J, Jastreboff A, le Roux C, Sattar N, Aizenberg D, Mao H, Zhang S, Ahmad N, Bunck M, Benabbad I, Zhang X, investigators S, Abalos F, Manghi F, Zaidman C, Vico M, Aizenberg D, Costanzo P, Serra L, MacKinnon I, Hissa M, Vidotti M, Saraiva J, Alves B, Franco D, Moratto O, Murthy S, Goyal G, Yamasaki Y, Sato N, Inoue S, Asakura T, Shestakova M, Khaykina E, Troshina E, Vorokhobina N, Ametov A, Tu S, Yang C, Lee I, Huang C, Ou H, Freeman G, Machineni S, Klein K, Sultan S, Parsa A, Otero-Martinez J, Gonzalez A, Bhargava A, Brian S, Ince C, Plantholt S, Cole J, Lacour A, Vega D, de Souza J, Rohlf J, St. John R, Horowitz B, Audish H, Galindo R, Umpiperrez G, Ard J, Curtis B, Garvey W, Fraser N, Mandry J, Mohseni R, Mayfield R, Powell T, Vance C, Ong S, Lewy-Alterbaum A, Murray A, Al-Karadsheh A, Yacoub T, Roberts K, Fried D, Rosenstock J, Pulla B, Bode B, Frias J, Klaff L, Brazg R, Van J, Tan A, Briskin T, Rhee M, Chaicha-Brom T, Hartley P, Nunez L, Cortes-Maisonet G, Soucie G, Hsia S, Jones T. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. The Lancet 2023, 402: 613-626. PMID: 37385275, DOI: 10.1016/s0140-6736(23)01200-x.Peer-Reviewed Original ResearchConceptsType 2 diabetesBody mass indexTreatment discontinuationAdverse eventsBodyweight reductionWeight managementGlucagon-like peptide-1 receptor agonistsInteractive web response systemPeptide-1 receptor agonistsGlucose-dependent insulinotropic polypeptideComputer-generated random sequenceFrequent adverse eventsPlacebo-controlled trialSerious adverse eventsIncretin-based therapiesPhase 3 trialWeb response systemTreatment of obesityWeekly tirzepatideCoprimary endpointsRescue therapySafety endpointWeek 72Safety profileStudy treatmentTriple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial
Jastreboff A, Kaplan L, Frías J, Wu Q, Du Y, Gurbuz S, Coskun T, Haupt A, Milicevic Z, Hartman M. Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. New England Journal Of Medicine 2023, 389: 514-526. PMID: 37366315, DOI: 10.1056/nejmoa2301972.Peer-Reviewed Original ResearchConceptsBody weightPercentage changePlacebo groupEnd pointGlucagon-like peptide-1Glucose-dependent insulinotropic polypeptideLower starting doseWeight-related conditionsCommon adverse eventsPlacebo-controlled trialPrimary end pointSecondary end pointsBody mass indexTreatment of obesityDose-dependent increaseDose-response relationshipWeight reductionStarting doseAdverse eventsInsulinotropic polypeptideHeart ratePeptide-1Side effectsGlucagon receptorWeeksNew Frontiers in Obesity Treatment: GLP-1 and Nascent Nutrient-Stimulated Hormone-Based Therapeutics
Jastreboff A, Kushner R. New Frontiers in Obesity Treatment: GLP-1 and Nascent Nutrient-Stimulated Hormone-Based Therapeutics. Annual Review Of Medicine 2023, 74: 125-139. PMID: 36706749, DOI: 10.1146/annurev-med-043021-014919.Peer-Reviewed Original ResearchConceptsGLP-1 RAsGlucagon-like peptide-1 receptor agonistsPeptide-1 receptor agonistsAnti-obesity therapeuticsTreatment of obesityMechanism-based treatmentsNeurobiology of obesityObesity treatmentReceptor agonistGLP-1Obesity therapeuticsEffective treatmentObesityHalf of AmericansFirst agentTreatmentTherapeuticsAgonistsAgents
2022
Obstacles and opportunities in managing coexisting obesity and CKD: Report of a scientific workshop cosponsored by the National Kidney Foundation and The Obesity Society
Friedman AN, Schauer PR, Beddhu S, Kramer H, le Roux C, Purnell JQ, Sunwold D, Tuttle KR, Jastreboff AM, Kaplan LM. Obstacles and opportunities in managing coexisting obesity and CKD: Report of a scientific workshop cosponsored by the National Kidney Foundation and The Obesity Society. Obesity 2022, 30: 2340-2350. PMID: 36268562, DOI: 10.1002/oby.23599.Peer-Reviewed Original ResearchConceptsChronic kidney diseaseNational Kidney FoundationManagement of obesityKidney diseaseMetabolic surgeryObesity managementKidney FoundationObesity SocietyWeight loss medicationsLifestyle interventionAdverse outcomesTransplant surgeryObesity medicineEffective treatmentObesityProvider engagementSurgeryBeneficial effectsMedicine expertsMultidisciplinary approachDiseasePatientsScientific workshopConclusionCollaborative action planObstacles and Opportunities in Managing Coexisting Obesity and CKD: Report of a Scientific Workshop Cosponsored by the National Kidney Foundation and The Obesity Society
Friedman AN, Schauer PR, Beddhu S, Kramer H, le Roux CW, Purnell JQ, Sunwold D, Tuttle KR, Jastreboff AM, Kaplan LM. Obstacles and Opportunities in Managing Coexisting Obesity and CKD: Report of a Scientific Workshop Cosponsored by the National Kidney Foundation and The Obesity Society. American Journal Of Kidney Diseases 2022, 80: 783-793. PMID: 36280397, DOI: 10.1053/j.ajkd.2022.06.007.Peer-Reviewed Original ResearchConceptsChronic kidney diseaseNational Kidney FoundationKidney diseaseMetabolic surgeryObesity managementKidney FoundationObesity SocietyWeight loss medicationsManagement of obesityLifestyle interventionAdverse outcomesTransplant surgeryObesity medicineEffective treatmentObesityProvider engagementSurgeryBeneficial effectsMedicine expertsMultidisciplinary approachDiseasePatientsScientific workshopConclusionCollaborative action planTirzepatide Once Weekly for the Treatment of Obesity. Reply.
Jastreboff AM, Aronne LJ, Stefanski A. Tirzepatide Once Weekly for the Treatment of Obesity. Reply. New England Journal Of Medicine 2022, 387: 1434-1435. PMID: 36239655, DOI: 10.1056/nejmc2211120.Peer-Reviewed Original ResearchTirzepatide Once Weekly for the Treatment of Obesity
Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, Kiyosue A, Zhang S, Liu B, Bunck MC, Stefanski A. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal Of Medicine 2022, 387: 205-216. PMID: 35658024, DOI: 10.1056/nejmoa2206038.Peer-Reviewed Original ResearchConceptsBody weightTreatment discontinuationAdverse eventsGlucagon-like peptide-1 receptor agonistsPeptide-1 receptor agonistsGlucose-dependent insulinotropic polypeptidePercentage changeDose escalation periodWeight-related complicationsCommon adverse eventsCoprimary end pointsBody mass indexSubstantial global morbidityTreatment of obesityMean percentage changePercentage of participantsMean body weightWeight reductionCardiometabolic measuresTreat populationPlacebo groupWeek 72Mean BMIWeekly dosesDose escalation
2021
Impact of Obesity on Heart Transplantation Outcomes
Chouairi F, Milner A, Sen S, Guha A, Stewart J, Jastreboff AM, Mori M, Clark KA, Miller PE, Fuery MA, Rogers JG, Notarianni A, Jacoby D, Maulion C, Anwer M, Geirsson A, Desai NR, Ahmad T, Mullan CW. Impact of Obesity on Heart Transplantation Outcomes. Journal Of The American Heart Association 2021, 10: e021346. PMID: 34854316, PMCID: PMC9075353, DOI: 10.1161/jaha.121.021346.Peer-Reviewed Original ResearchConceptsBody mass indexHigher BMI categoriesImpact of obesityHeart transplantation outcomesBMI categoriesTransplantation outcomesHeart transplantationHigher body mass indexAllocation system changeAdvanced heart failureOrgan Sharing databaseObese BMI categoriesVentricular assist deviceNew Organ ProcurementPosttransplant deathPosttransplantation deathPosttransplant mortalityBackground PatientsBMI 18.5Adult patientsCohort studyHeart failureHeart transplantSharing databaseWaitlist deathsTreating the Chronic Disease of Obesity
Gossmann M, Butsch WS, Jastreboff AM. Treating the Chronic Disease of Obesity. Medical Clinics Of North America 2021, 105: 983-1016. PMID: 34688422, DOI: 10.1016/j.mcna.2021.06.005.Peer-Reviewed Original ResearchConceptsChronic diseasesIntensive lifestyle interventionAvailable therapeutic modalitiesPrimary care providersTreatable chronic diseaseCare of patientsAntiobesity pharmacotherapiesBariatric surgeryLifestyle interventionSafe therapyComprehensive careTherapeutic modalitiesCare providersTreatment approachesObesityPatientsDiseaseCarePharmacotherapySurgeryTherapyDiagnosisCOVID‐19 vaccines are effective in people with obesity: A position statement from The Obesity Society
Butsch WS, Hajduk A, Cardel MI, Donahoo WT, Kyle TK, Stanford FC, Zeltser LM, Kotz CM, Jastreboff AM. COVID‐19 vaccines are effective in people with obesity: A position statement from The Obesity Society. Obesity 2021, 29: 1575-1579. PMID: 34212511, PMCID: PMC8441899, DOI: 10.1002/oby.23251.Peer-Reviewed Original ResearchConceptsCOVID-19 vaccineObesity SocietyCOVID-19-associated hospitalizationPosition statementEfficacy of vaccinesSARS-CoV-2Pfizer-BioNTechAvailable vaccinesUS FoodDrug AdministrationObesityVaccineEmergency useHigh efficacyPeer-reviewed literatureScientific evidenceCOVID-19EfficacyTime of publicationBriefing documentsDefinitive wayHospitalizationPatientsVaccinationAdministrationLower synaptic density is associated with psychiatric and cognitive alterations in obesity
Asch RH, Holmes SE, Jastreboff AM, Potenza MN, Baldassarri SR, Carson RE, Pietrzak RH, Esterlis I. Lower synaptic density is associated with psychiatric and cognitive alterations in obesity. Neuropsychopharmacology 2021, 47: 543-552. PMID: 34294874, PMCID: PMC8674236, DOI: 10.1038/s41386-021-01111-5.Peer-Reviewed Original ResearchConceptsStress-related psychiatric disordersBody mass indexLower synaptic densitySynaptic densityPsychiatric disordersPsychiatric diagnosisOverweight/obesityNormal-weight individualsNormal-weight participantsSerious medical conditionPositron emission tomographyStress-related psychopathologyDorsolateral prefrontal cortexOverweight/Mass indexWeight participantsWeight individualsHealthy controlsTension/anxietyAssociated symptomatologyMedical conditionsIntervention development effortsObesityCognitive alterationsPsychiatric groupsDietary supplements and alternative therapies for obesity: A Perspective from The Obesity Society’s Clinical Committee
Kidambi S, Batsis JA, Donahoo WT, Jastreboff AM, Kahan S, Saunders KH, Heymsfield SB. Dietary supplements and alternative therapies for obesity: A Perspective from The Obesity Society’s Clinical Committee. Obesity 2021, 29: 1095-1098. PMID: 34159756, DOI: 10.1002/oby.23189.Peer-Reviewed Original Research
2019
Commentary from the American Association of Clinical Endocrinologists on the U.S. Preventive Services Task Force Recommandations Regarding Weight Loss Interventions
Garvey WT, Jastreboff AM. Commentary from the American Association of Clinical Endocrinologists on the U.S. Preventive Services Task Force Recommandations Regarding Weight Loss Interventions. Endocrine Practice 2019, 25: 394-395. PMID: 31013160, DOI: 10.4158/ep-2018-0597.Commentaries, Editorials and Letters
2018
Obesity as a Disease: The Obesity Society 2018 Position Statement
Jastreboff AM, Kotz CM, Kahan S, Kelly AS, Heymsfield SB. Obesity as a Disease: The Obesity Society 2018 Position Statement. Obesity 2018, 27: 7-9. PMID: 30569641, DOI: 10.1002/oby.22378.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsPreventing Childhood Obesity Through a Mindfulness-Based Parent Stress Intervention: A Randomized Pilot Study
Jastreboff AM, Chaplin TM, Finnie S, Savoye M, Stults-Kolehmainen M, Silverman WK, Sinha R. Preventing Childhood Obesity Through a Mindfulness-Based Parent Stress Intervention: A Randomized Pilot Study. The Journal Of Pediatrics 2018, 202: 136-142.e1. PMID: 30241766, PMCID: PMC6203652, DOI: 10.1016/j.jpeds.2018.07.011.Peer-Reviewed Original ResearchConceptsChildhood obesityChild body mass indexGroup interventionPhysical activity counselingRandomized pilot studyBody mass indexChildhood obesity riskControl group interventionEarly childhood obesityStress interventionsActivity counselingMass indexObesity riskPhysical activityTherapeutic mechanismObesityGroup attendanceRisk 2Pilot studyInterventionSignificant increaseLow-income parentsGreater improvementRiskParent-child dyads
2016
Elevated Dopamine D2/3 Receptor Availability in Obese Individuals: A PET Imaging Study with [11C](+)PHNO
Gaiser EC, Gallezot JD, Worhunsky PD, Jastreboff AM, Pittman B, Kantrovitz L, Angarita GA, Cosgrove KP, Potenza MN, Malison RT, Carson RE, Matuskey D. Elevated Dopamine D2/3 Receptor Availability in Obese Individuals: A PET Imaging Study with [11C](+)PHNO. Neuropsychopharmacology 2016, 41: 3042-3050. PMID: 27374277, PMCID: PMC5101552, DOI: 10.1038/npp.2016.115.Peer-Reviewed Original ResearchConceptsBody mass indexVentral striatumObese individualsD2/3R availabilityOB individualsReward regionsSubstantia nigra/ventral tegmental areaDopamine D2/3 receptor availabilityNormal-weight individualsTreatment of obesityVentral tegmental areaNovel pharmacologic targetsD2/3 receptor availabilitySN/VTAAgonist tracersOverweight cohortMass indexWeight individualsTegmental areaBrain reward regionsAntagonist tracersPharmacologic targetReceptor availabilitySecondary analysisNW individualsAmerican Association of Clinical Endocrinologists and American College of Endocrinology Comprehensive Clinical Practice Guidelines for Medical Care of Patients with Obesity
Garvey WT, Mechanick JI, Brett EM, Garber AJ, Hurley DL, Jastreboff AM, Nadolsky K, Pessah-Pollack R, Plodkowski R, Guidelines R. American Association of Clinical Endocrinologists and American College of Endocrinology Comprehensive Clinical Practice Guidelines for Medical Care of Patients with Obesity. Endocrine Practice 2016, 22: 842-884. PMID: 27472012, DOI: 10.4158/ep161356.esgl.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsClinical practice guidelinesAmerican CollegePractice guidelinesMedical careAdiposity-based chronic diseaseDetailed evidence-based recommendationsObesity clinical practice guidelinesReal-world medical careComprehensive clinical practice guidelinesClinical Endocrinologists ACEWeight-related complicationsIndividualization of careSelection of therapyEvidence-based recommendationsMedical care planAmerican AssociationQuality of lifeHigh-quality careAACE protocolRecommendation gradesClinical EndocrinologistsClinical evidenceChronic diseasesTreatment goalsCare plans